x220

Document Sample
x220 Powered By Docstoc
					Topic LabelTopic                   Institute
                        Percent about Topic    Code   Grant    Title       PI
HIV        [t220]-hiv-infected58.9 NINDS       R01             Co-evolution of HIV-1 Regulators in CNS Disease
                                                      5R01NS046263-03      WIGDAHL, BRIAN
HIV        [t220]-hiv-infected54.1 NIAID       R01             Antiretroviral Therapy for HIV-2 Infection in Senegal
                                                      5R01AI060466-02      GOTTLIEB, GEOFFREY S.
HIV        [t220]-hiv-infected 54 NIAID        K23             Persistent Reservoirs of HIV-1 Infection
                                                      5K23AI050449-05      FIERER, DANIEL SETH.
HIV        [t220]-hiv-infected48.9 NIAID       R21             HIV IN      GUPTA, PHALGUNI
                                                      5R21AI065392-02 SEMEN FROM INFECTED SUBJECTS FROM IND
HIV        [t220]-hiv-infected48.3 NIGMS       S06             HIV ResidualLORENZO, ERIC
                                                      5S06GM008239-210008 Replication and Drug Holidays
HIV        [t220]-hiv-infected 44 NIAID        R01             HIV Vaccines on Latent Reservoirs
                                                      1R01AI062446-01A2 PERSAUD, DEBORAH in Young Adults on HA
HIV        [t220]-hiv-infected43.7 NIGMS       S06             Seminal Compartment as a Drug Sanctuary and Potential
                                                      5S06GM008239-210005  HILL, MARTIN D.
HIV        [t220]-hiv-infected43.5 NIDA        R01             High Specificity HIV-1 Markers L.
                                                      5R01DA019807-03      WIGDAHL, BRIAN Predictive of Neuro-AIDS
HIV        [t220]-hiv-infected43.3 NIAID       R01             Studies     SILVESTRI, GUIDO
                                                      7R01AI066998-02 of Natural SIV Infection of Sooty Mangabeys
HIV        [t220]-hiv-infected43.2 NIAID       R01             SIGNIFICANCE OF LOW LEVEL F.
                                                      5R01AI051178-05      SILICIANO, ROBERT VIREMIA IN PATIENTS
HIV        [t220]-hiv-infected42.9 NIAID       R01             APOBEC3G/CEM15 Inhibition of Lentivirus Replication
                                                      5R01AI058864-03      LANDAU, NATHANIEL R.
HIV        [t220]-hiv-infected42.4 NINDS       R01             Role of      Tat protein in pathogenesis of HIV dementia
                                                      5R01NS039253-08HIVNATH, AVINDRA
HIV        [t220]-hiv-infected42.3 NIAID       R01             HIV 1 specific T cell clones
                                                      5R01AI028568-18      WALKER, BRUCE D.
HIV        [t220]-hiv-infected42.3 NIAID       R01             Pathogenesis of SIV in African green monkeys
                                                      5R01AI064066-02      PANDREA, IVONA
HIV        [t220]-hiv-infected41.5 NIMH        R01             Genetics Simian Immunodeficiency Virus Encephalopa
                                                      5R01MH067734-04 ofGONZALEZ-SCARANO, FRANCISCO A.
HIV        [t220]-hiv-infected41.4 NIAID       R01             HIV Vif-mediated Degradation H. APOBEC3G
                                                      5R01AI062555-03      GABUZDA, DANA of
HIV        [t220]-hiv-infected40.4 NIAID       R01             Roles of Vif Variants and APOBEC3s in HIV-1/AIDS
                                                      2R01AI049729-06A2 KABAT, DAVID
HIV        [t220]-hiv-infected40.1 NINDS       R01             Predicting MCARTHUR, JUSTIN C
                                                      5R01NS049465-03 progression of NeuroAIDS
HIV        [t220]-hiv-infected40.1 NIAID       R01             Clearing MARGOLIS, DAVID M.
                                                      5R01AI064074-03 Persistently HIV-Infected CD4+ T Lymphocytes
HIV        [t220]-hiv-infected39.7 NICHD       R01             SEMEN IN TRANSMISSION OF
                                                      1R01HD052436-01A1 GUPTA, PHALGUNI HIV
HIV        [t220]-hiv-infected39.3 NIMH        R01             CNS Viral HAAS, DAVID W.
                                                      5R01MH071205-02 Dynamics and Cellular Immunity During AIDS
HIV        [t220]-hiv-infected38.5 NIAID       R21             Role of     MONDAL, DEBASIS
                                                      5R21AI064048-02 P-gp in perivascular HIV-1 sanctuary and HAART
HIV        [t220]-hiv-infected38.5 NIAID       R01             Activation-induced Non-responsiveness causes HIV Prog.
                                                      5R01AI065328-02      HORTON, HELEN
HIV        [t220]-hiv-infected38.3 NIAID       R01             CTL Responses to Regulatory and Accessory HIV-1 Prote
                                                      5R01AI050429-05      ALTFELD, MARCUS
HIV        [t220]-hiv-infected38.2 NIAID       R01             HIV/TB      WHALEN, CHRISTOPHER C.
                                                      5R01AI051219-04 in Uganda: Punctuated Antiretroviral Therapy
HIV        [t220]-hiv-infected38.2 NIAID       R01             Markers NOVITSKY, VLADIMIR A.
                                                      5R01AI057027-02 of Viral Set Point in Primary HIV-1C Infection
HIV        [t220]-hiv-infected38.1 NIAID       R01             Molecular MechanismBRYAN R. Function
                                                      5R01AI057099-03      CULLEN, of HIV-1 Vif
HIV        [t220]-hiv-infected 38 NIAID        R01             Reservoirs of drug-resistant HIV-1
                                                      5R01AI058723-02      FRENKEL, LISA M.
HIV        [t220]-hiv-infected37.9 NINDS       R21             Bone Marrow Macrophage Differentiation & HIV-CNS Dise
                                                      5R21NS050077-02      BABAS, TAHAR
HIV        [t220]-hiv-infected37.8 NIAID       R21             SIV Deltavif Reservoirs in Vivo
                                                      1R21AI068654-01A2 SPARGER, ELLEN ELIZABETH.
HIV        [t220]-hiv-infected37.7 NIMH        R01             OTK18       IKEZU, TSUNEYA
                                                      5R01MH072539-02Regulation in HIV-1 associated dementia
HIV        [t220]-hiv-infected37.5 NIGMS       S06             Therapeutic Immunization in Monkey Model of AIDS
                                                      5S06GM008239-210007  KUMAR, ANIL
HIV        [t220]-hiv-infected37.2 NIAID       R01             Immune PETERSON, SIV infected macaques
                                                      5R01AI035522-14 reconstitution in DOLORES MURL.
HIV        [t220]-hiv-infected37.1 NHLBI       R01             Cellular    CLEMENTS, Control SIV
                                                      5R01HL075840-04 Mechanisms thatJANICE E. & Development of P
HIV        [t220]-hiv-infected37.1 NIDDK       R01             HIV Reservior & CD4 Repopulation in Gut lymphoid tissue
                                                      5R01DK061297-05      DANDEKAR, SATYA
HIV        [t220]-hiv-infected 37 NINDS        R01             Astrocyte-Marcophage ASHOK
                                                      1R01NS050064-01A2 CHAUHAN,Interactions in HIV-1 Regulation
HIV        [t220]-hiv-infected36.8 NINDS       R01             HIV-1 Proviral DNA and BRUCE T.
                                                      1R01NS053345-01A2 SHIRAMIZU,Monocyte Phenotype in Relation
HIV        [t220]-hiv-infected36.5 NIAID       R21             Viral Cytopathicity in CD4-Low SIV Passaged Mangabeys
                                                      5R21AI060451-02      PETERSON, DOLORES MURL.
HIV        [t220]-hiv-infected36.5 NIMH        R01             SIV Encephalitis and Disease A.
                                                      5R01MH071151-02 WILEY, CLAYTONProgression
HIV        [t220]-hiv-infected36.4 NIAID       R01             Nef Function
                                                      3R01AI033331-13S1 GARCIA-MARTINEZ, J. VICTOR.
HIV        [t220]-hiv-infected36.3 NIAID       R01             Nef Function ARCIA-MARTINEZ, J. VICTOR.
                                                      5R01AI033331-13      G
HIV        [t220]-hiv-infected36.1 NIAID       R01             Cellular    CAO, HUYEN L.
                                                      5R01AI043754-07 Immune Response to non-B Clade HIV Infection
HIV        [t220]-hiv-infected36.1 NIAID       R21             Peptide     DONAHUE, JOHN P.
                                                      1R21AI068490-01 Inhibitors of HIV-1 Vif Function
HIV        [t220]-hiv-infected35.9 NHLBI       R01             Impact of TOOSSI, ZAHRA J.
                                                      3R01HL051636-13S1Tuberculosis on HIV Disease
HIV        [t220]-hiv-infected35.8 NIAID       R01             Drug development DAVID
                                                      1R01AI067105-01A1 KABAT,for Vif-APOBEC3G in HIV-1/AIDS
HIV        [t220]-hiv-infected35.6 NIMH        R01             Genetics Neuropathogenic SIV Infection
                                                      5R01MH067769-04 ofNOVEMBRE, FRANCIS J.
HIV        [t220]-hiv-infected35.5 NIAID       R21             Role of     STEPHENS, EDWARD BRICE.
                                                      5R21AI064019-02 Targeted Mutations in ViF on SHIV Pathogenesis
HIV        [t220]-hiv-infected35.4 NIAID       R01             Gender      JAMIESON, BETH D.
                                                      5R01AI058845-03 Differences In HIV-1 Pathogenesis
HIV        [t220]-hiv-infected35.4 NHLBI       R01             Impact      TOOSSI, ZAHRA J.
                                                      5R01HL051636-13of Tuberculosis on HIV Disease
HIV        [t220]-hiv-infected34.9 NIAID       R21             Mechanisms of HIV-1 proviral inactivation vs latency
                                                      5R21AI064031-02      O'DOHERTY, UNA T.
HIV        [t220]-hiv-infected34.8 NINDS       R21             Targeting WU, YUNTAO
                                                      5R21NS051130-02 Brain Macrophages by a novel lentiviral vector
HIV   [t220]-hiv-infected34.5   NICHD   R01            Pediatric VAN RIE, ANNELIES
                                              1R01HD053216-01 HIV-encephalopathy in DRC: effect of ART & rol
HIV   [t220]-hiv-infected34.5   NIAID   R01            Cytidine    ZHANG, HUI
                                              5R01AI058798-03 deaminase and HIV-1 replication
HIV   [t220]-hiv-infected34.3   NIAID   R01            Inhibition HIV1 Replication by Cytotoxic Lymphocytes
                                              5R01AI030914-13 ofWALKER, BRUCE D.
HIV   [t220]-hiv-infected33.9   NIAID   K08            Non-nucleoside Reverse Transcriptive Hypersensitivity
                                              5K08AI051199-05      SHULMAN, NANCY S.
HIV   [t220]-hiv-infected33.8   NIAID   R21            Novel Assays to IdentifyDANA H.
                                              5R21AI067032-02      GABUZDA, HIV Vif Inhibitors
HIV   [t220]-hiv-infected33.6   NIAID   R01            Mechanisms of HIV-1 latency in CD4+ T lymphocytes
                                              5R01AI035381-12      RICE, ANDREW P.
HIV   [t220]-hiv-infected33.5   NIAID   R03            Studies of DE BRUYN, GUY
                                              1R03AI070079-01A1 Early HIV-1 subtype C Infection in South Africa
HIV   [t220]-hiv-infected33.1   NINDS   R01            In vivo proton MRS BRADFORD A injury in HIV infection
                                              5R01NS036524-07      NAVIA, studies:cerebral
HIV   [t220]-hiv-infected 33    NIAID   R01            Optimizing NNRTI Doses in Patients with HIV and TB
                                              5R01AI058839-02      BLASCHKE, TERRENCE F.
HIV   [t220]-hiv-infected32.8   NICHD   K23            A Prospective StudyNATASCHA Immune Correlates in Pe
                                              5K23HD051456-02      CHING, of Viral and
HIV   [t220]-hiv-infected32.7   NCI     R01            Antiretroviral TherapyJEFFREY N.
                                              5R01CA119903-02      MARTIN, of AIDS-Related Kaposi's Sarcoma
HIV   [t220]-hiv-infected32.7   NIAID   R01            Antiviral   CU-UVIN, SUSAN
                                              5R01AI040350-09 Therapy and HIV in the Genital Tract of Women
HIV   [t220]-hiv-infected32.6   NIAID   R01            HIV-1 Inhibition by Delivery of 2-5OAS
                                              2R01AI034765-07A2 SUHADOLNIK, ROBERT J.& PKR Genes
HIV   [t220]-hiv-infected32.4   NIAID   U01            ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM IN
                                              3U01AI046370-05S2 MILDVAN, DONNA
HIV   [t220]-hiv-infected32.4   NCI     R01            HIV-1 Vpr CHEN, IRVIN SY.
                                              5R01CA070018-12 Induces G2 Cell Cycle Arrest and Apoptosis
HIV   [t220]-hiv-infected32.3   NIAID   R01            Role of specific Nef functions in AIDS pathogenesis
                                              1R01AI067057-01A2 KIRCHHOFF, FRANK
HIV   [t220]-hiv-infected32.3   NIAID   R01            Studies     SILVESTRI, GUIDO
                                              5R01AI052755-05 of the HIV-associated cell cycle disease
HIV   [t220]-hiv-infected32.3   NIAID   R01            Immune control of SIVagm replication in vivo
                                              1R01AI065335-01A1 SCHMITZ, JOERN E.
HIV   [t220]-hiv-infected32.1   NIAID   U01            Immunologic & Virologic Features of Early HIV Infection
                                              5U01AI041531-09      LEVY, JAY A.
HIV   [t220]-hiv-infected31.9   NIMH    R01            Tat Interaction JOHNNY J.
                                              5R01MH065158-05 HE,with LRP and Its Role in AIDS Dementia
HIV   [t220]-hiv-infected31.4   NIMH    R01            Tachykinins Mononuclear Phagocytes
                                              5R01MH049981-12 DOUGLAS, STEVEN D. and HIV-1 Infection
HIV   [t220]-hiv-infected31.3   NIAID   U01            Understanding and Altering the Virologic Setpoint
                                              5U01AI041534-09      MARKOWITZ, MARTIN H.
HIV   [t220]-hiv-infected31.1   NIAID   R01            Role of macrophages CECILIA M.
                                              1R01AI068525-01A1 SHIKUMA,in HIV Lipoatrophy
HIV   [t220]-hiv-infected31.1   NICHD   R01            Optimizing JOHN-STEWART, GRACE C.
                                              2R01HD023412-16A1 pediatric HIV-1 therapy
HIV   [t220]-hiv-infected30.9   NIAID   R21            T regulatory cells in Rhesus Macaques and African green
                                              1R21AI069935-01A1 PANDREA, IVONA
HIV   [t220]-hiv-infected30.9   NIAID   R01            Antiretroviral Therapy and HIV-1 Infectivity in Women
                                              5R01AI058698-02      MCCLELLAND, RAYMOND SCOTT.
HIV   [t220]-hiv-infected30.8   NIAID   R01            Biochemical Pharmacology of Anti-HIV Compounds
                                              2R01AI038204-12A2 CHENG, YUNG-CHI
HIV   [t220]-hiv-infected30.7   NINDS   R01            Microglia WILLIAMS, KENNETH C
                                              5R01NS037654-08 and SIV Neuropathogenesis
HIV   [t220]-hiv-infected30.7   NIMH    R21            Proteomic BOWSER, ROBERT SIV
                                              5R21MH073429-02 profiling of CSF duringP. infection
HIV   [t220]-hiv-infected30.7   NIMH    R21            HIV Clade ELLIS, RONALD J.
                                              1R21MH076651-01 on Cognitive and Neurological Disorders Brazil
HIV   [t220]-hiv-infected30.5   NIAID   R37            Immune PERELSON, ALAN
                                              5R37AI028433-16 System Modeling/HIV S.
HIV   [t220]-hiv-infected30.4   NIAID   R01            MOLECULAR MECHANISMS
                                              1R01AI065362-01A2 BOSTIK, PAVEL OF CD4+ T CELL DYSFUN
HIV   [t220]-hiv-infected30.4   NIAID   K24            Therapeutic Strategies for HIV Disease
                                              5K24AI051982-06      HAVLIR, DIANE V.
HIV   [t220]-hiv-infected30.3   NINDS   R01            Glial Cell CLEMENTS, JANICE E
                                              5R01NS047984-03 Inflammatory Mechanisms & CNS Regulation
HIV   [t220]-hiv-infected30.2   NIAID   U01            UAB AIEDRP: Immune Control and Escape in Acute Infec
                                              5U01AI041530-09      KILBY, J M.
HIV   [t220]-hiv-infected30.2   NINDS   R01            Mechanisms of HIV-Induced PNS Disease: The SIV Maca
                                              1R01NS055651-01A1 MANKOWSKI, JOSEPH L
HIV   [t220]-hiv-infected30.1   NIDA    R01            AIDS encephalopathy and HIV disease: role of opioids
                                              7R01DA015628-06      NAIR, MADHAVAN P.
HIV   [t220]-hiv-infected30.1   NIAID   R01            ChemokineREINHART, During SIV Infection & AIDS
                                              5R01AI060422-02       Modulation TODD A.
HIV   [t220]-hiv-infected 30    NIMH    R01            HIV NEUROCOGNITIVE DISORDERS--CSF HIV RNA AN
                                              3R01MH058076-08S1 ELLIS, RONALD J.
HIV   [t220]-hiv-infected 30    NIAID   R01            Dissecting HIV integrationUNA T.
                                              5R01AI058862-03      O'DOHERTY, vs production in CD4+ T cells
HIV   [t220]-hiv-infected29.9   NIAID   R01            Regulation and Action WARNER C.
                                              5R01AI065329-02      GREENE, of APOBEC3G
HIV   [t220]-hiv-infected29.8   NHLBI   R01            Pulmonary CD4+ T-Cell Repopulation in Immune Recons
                                              5R01HL083468-02      KNOX, KENNETH S.
HIV   [t220]-hiv-infected29.8   NIAID   U01            ADULT AIDS CLINICAL TRIALS UNIT
                                              3U01AI027665-18S2 ABERG, JUDITH
HIV   [t220]-hiv-infected29.8   NIAID   R01            Role of     YU, ubiquitin ligasae in HIV Vif function
                                              5R01AI062644-03 Cul5 E3XIAO-FANG
HIV   [t220]-hiv-infected29.7   NIAID   R01            Immune YANG, OTTO O.
                                              5R01AI051970-05 Pressure on HIV-1 Nef by Cytotoxic T Lymphocy
HIV   [t220]-hiv-infected29.7   NIAID   R21            Impact      ABBAS, UME L.
                                              5R21AI064092-02 of Antiretrovirals on the Spread of HIV
HIV   [t220]-hiv-infected29.6   NIGMS   K14            Transactivation Potency of Latent
                                              5K14GM068397-04 ROMEO, JOSEPH M. HIV Quasispecies
HIV   [t220]-hiv-infected29.6   NIAID   R21            Overcoming blocks to HIV-1 replication in rhesus macaqu
                                              1R21AI071896-01      HATZIIOANNOU, THEODORA
HIV   [t220]-hiv-infected29.5   NIA     R01            CLINICAL GEBO, KELLY ELDERLY HIV PATIENTS
                                              1R01AG026250-01A2 OUTCOMES IN A.
HIV   [t220]-hiv-infected29.2   NIAID   R01            Drug Resistance and Pathogenesis A. Subtype C HIV-1
                                              5R01AI060399-02      KATZENSTEIN, DAVID in
HIV   [t220]-hiv-infected29.1   NIAID   K23            Effect      BISSON, GREGORY P.
                                              5K23AI058881-03of GBV-C on HIV
HIV   [t220]-hiv-infected29.1   NIAID   U01            Anti-HIV MBOUP, SOULEYMANE
                                              5U01AI052734-04 Therapy in Senegal, West Africa
HIV   [t220]-hiv-infected29.1   NIAID   R01            HIV-1       GOLDFELD, pathogen
                                              5R01AI065285-02regulation by MTb:ANNE E. and host factor
HIV   [t220]-hiv-infected 29    NIAID   R01            Actions of ZHENG, YONG-HUI
                                              1R01AI063944-01A2 Vif and APOBEC3 proteins in HIV-1 Replication
HIV   [t220]-hiv-infected 29    NIAID   U01            AIDS CLINICAL TRIALS UNIT
                                              3U01AI027666-18S2 ZOLOPA, ANDREW
HIV   [t220]-hiv-infected 29    NIMH    R01            Predicting PULLIAM, D LYNN.
                                              5R01MH073478-02 HAD using Monocyte Profiling and Neuroimagin
HIV   [t220]-hiv-infected28.8   NIAID   R01            HIV-1-specific CD4 Cells inERIC S. Pathogenesis
                                              5R01AI040873-09      ROSENBERG, Disease
HIV   [t220]-hiv-infected28.8   NIAID   K23            The Determinants of T Cell W.
                                              5K23AI065244-02      HUNT, PETER Activation in HIV Infection
HIV   [t220]-hiv-infected28.8   NIDA    R01            HIV Disease Outcomes in Drug Users in Clinical Practice
                                              5R01DA011602-09      MOORE, RICHARD D.
HIV   [t220]-hiv-infected28.7   NIAID   R01            HIV-1       SIMON, VIVIANA A.
                                              5R01AI064001-02evolution driven by intracellular defenses
HIV   [t220]-hiv-infected28.6   NIDDK   R37            HIV IN SEMEN-EFFECTS OFS.
                                              5R37DK049381-11      COHEN, MYRON STDS AND ANTIVIRAL TH
HIV   [t220]-hiv-infected28.5   NIAID   R01            Latent       Reservoirs ROBERT F.
                                              5R01AI043222-08Viral SILICIANO, in HIV 1 Infection
HIV   [t220]-hiv-infected28.5   NHLBI   R01            Pathobiology of HIV(SIV)-Induced Angioproliferative Pul*
                                              5R01HL083491-02      FLORES, SONIA C.
HIV   [t220]-hiv-infected28.4   NIDA    R01            AIDS encephalopathy and HIV disease: role of opioids
                                              5R01DA015628-05      NAIR, MADHAVAN P.
HIV   [t220]-hiv-infected28.4   NIDA    R01            HIV-Encephalitis and Cocaine
                                              1R01DA020392-01A1 BUCH, SHILPA J. Abuse: Mechanism of Syne
HIV   [t220]-hiv-infected28.3   NIAID   U01            MULTICENTER AIDS COHORT STUDY
                                              5U01AI035039-14      PHAIR, JOHN P.
HIV   [t220]-hiv-infected28.3   NIAID   R01            HIV Replication and Thymopoiesis in Adolescents
                                              5R01AI051996-04      KROGSTAD, PAUL A.
HIV   [t220]-hiv-infected28.3   NICHD   R03            Innate and PAHWA, SAVITA
                                              1R03HD052154-01 adaptive immunity in children starting anir*
HIV   [t220]-hiv-infected28.3   NIAID   R01            Cell Mediated Immunity in HIV Infected Children
                                              5R01AI060379-02      NIXON, DOUGLAS F.
HIV   [t220]-hiv-infected28.2   NIDDK   R01            Molecular LAURENCE, JEFFREY C.
                                              5R01DK065511-02 basis for HIV therapy-linked osteopenia
HIV   [t220]-hiv-infected28.2   NIDA    R21            Use a novelHE, JOHNNY J.model to develop neuroAIDS t
                                              1R21DA022986-01        Tat transgenic
HIV   [t220]-hiv-infected28.2   NCI     K23            The Epidemiologic Effects of HAART on HIV-related Anal
                                              1K23CA124318-01      CHIAO, ELIZABETH
HIV   [t220]-hiv-infected28.1   NHLBI   R01            Lipogenesis & Lipoprotein
                                              2R01HL065915-06A2 HUI, DAVID Y. Complications of HIV Therapy
HIV   [t220]-hiv-infected28.1   NIMH    R01            Activation of CD40 by HIV MARIO
                                              2R01MH064411-11A1 STEVENSON, and Role in AIDS Dementia
HIV   [t220]-hiv-infected 28    NIMH    R21            Macrophage Protein Fingerprints in S.
                                              5R21MH075662-02 CIBOROWSKI, PAWEL HIV-1 Dementia
HIV   [t220]-hiv-infected 28    NICHD   R01            Monitoring LALLEMANT, MARC J.
                                              5R01HD042964-03 HAART in HIV-infected parents in Thailand
HIV   [t220]-hiv-infected 28    NIDA    R03            Effect of VOLSKY, HIV-1 J.
                                              1R03DA022169-01 morphine on DAVIDneuroinvasion and brain chan
HIV   [t220]-hiv-infected 28    NIAID   R01            Foamy       MERGIA, AYALEW
                                              5R01AI039126-12 Virus Vector for Immunodeficiency Viruses Therap
HIV   [t220]-hiv-infected27.9   NIAID   R01            Pathogenesis of Clade C HIV D.
                                              1R01AI067073-01A1 WALKER, BRUCEInfection
HIV   [t220]-hiv-infected27.9   NIAID   R21            Interferon WOELK, Genes with Antiviral
                                              1R21AI065242-01A2 StimulatedCHRISTOPHER H. Properties to HI
HIV   [t220]-hiv-infected27.8   NIDA    R21            In Vivo Modeling of Methamphetamine and HIV Interaction
                                              1R21DA020394-01A2 BALDWIN, GAYLE C.
HIV   [t220]-hiv-infected27.8   NINDS   R01            PersistenceMARRA, T. pallidum inM Infection
                                              5R01NS034235-10        of CNS CHRISTINA HIV
HIV   [t220]-hiv-infected27.6   NIAID   U01            HIV Therapy & Interruption RCT in Resource Poor Clinic
                                              5U01AI051986-04      MONTANER, LUIS J.
HIV   [t220]-hiv-infected27.5   NIAID   R37            Induction Immunity by NINA
                                              5R37AI044628-08 ofBHARDWAJ, Non-Replicating HIV-1
HIV   [t220]-hiv-infected27.3   NIAID   R01            Retroviral Co-Infections: HIV, HTLV and Drug Abuse
                                              5R01AI049744-05      BEILKE, MARK A.
HIV   [t220]-hiv-infected27.3   NINDS   P01            Molecular GONZALEZ-SCARANO, Encephalopathy
                                              5P01NS027405-17 and Cellular Biology of HIVFRANCISCO A
HIV   [t220]-hiv-infected27.2   NIDA    R01            Retinoids ROYAL, WALTER
                                              5R01DA015311-06 and Substances of Abuse in HIV-1 Infection
HIV   [t220]-hiv-infected27.2   NIAID   R01            RepressionMARGOLIS, DAVID M. Pathway to Quiescenc
                                              5R01AI045297-10       of HIV Transcription-A
HIV   [t220]-hiv-infected27.1   NIAID   R01            Induction Apoptosis by HIV-1 vpr
                                              2R01AI049057-07A1 ofPLANELLES, VICENTE
HIV   [t220]-hiv-infected27.1   NIMH    R01            Targeting STRAYER, of the S.
                                              5R01MH070287-03 HIV infection DAVIDcns using gene delivery
HIV   [t220]-hiv-infected27.1   NIAID   R41            Suicide     FINKEL, TERRI H.
                                              1R41AI071927-01 of HIV-Infected Cells by TAT-Inducible shRNA
HIV   [t220]-hiv-infected27.1   NIDA    R01            Monocyte GABUZDA, DANA H.
                                              5R01DA016549-04 Viral Reservoirs in HIV-1 Dementia
HIV   [t220]-hiv-infected27.1   NIMH    R01            Mechanism and Therapy of SHIV Encephalitis in Macaque
                                              5R01MH068212-04 BUCH, SHILPA J.
HIV   [t220]-hiv-infected 27    NIAID   R01            Antiretroviral Therapy and the Hepatitis
                                              1R01AI065256-01A1 SHERMAN, KENNETH E. C Virus
HIV   [t220]-hiv-infected 27    NIAID   R01            Role of Regulatory T Cells in HIV A.
                                              1R01AI068524-01A1 CHOUGNET, CLAIREInfection
HIV   [t220]-hiv-infected26.9   NIAID   R01            Retroviral Co-Infections: HIV, HTLV and Drug Abuse
                                              7R01AI049744-06      BEILKE, MARK A.
HIV   [t220]-hiv-infected26.9   NINDS   R01            Improving ELMQUIST, WILLIAM F
                                              5R01NS042549-05 the CNS Delivery of Anti-retroviral Compounds
HIV   [t220]-hiv-infected26.8   NIAID   U01            Biologic    GREENBERG, PHILIP D.
                                              5U01AI054334-04 Activity of Transferred HIV-specific CD8 Clones
HIV   [t220]-hiv-infected26.8   NIMH    K23            Central     SPUDICH, SERENA S.
                                              5K23MH074466-02Nervous System Events in Primary HIV Infection
HIV   [t220]-hiv-infected26.8   NIAID   R01            A New       NARAYAN, OPENDRA
                                              5R01AI062340-04 DNA Vaccine Against HIV Disease in Macaques
HIV   [t220]-hiv-infected26.5   NIAID   R21            HIV-1 Vif: SCHIFFER, CELIA A.
                                              1R21AI067021-01A2 Targeting its molecular interactions
HIV   [t220]-hiv-infected26.5   NIAID   R21            Effect on KASHANCHI, FATAH
                                              1R21AI065236-01A1cdk inhibitor in HIV-1 replication
HIV   [t220]-hiv-infected26.5   NIAID   R01            Liver Disease and CHLOE L.Coinfection in the HAART era
                                              5R01AI060449-03      THIO, HIV-HBV
HIV   [t220]-hiv-infected26.4   NIAID   U01            HAART       SHAPIRO, Transmission to Infants In Botswa
                                              5U01AI066454-02 to Prevent HIVROGER L.
HIV   [t220]-hiv-infected26.4   NINDS   R01            Macrophage model of MARY JANE of HIV in the brain
                                              5R01NS039191-07      POTASH, the sanctuary
HIV   [t220]-hiv-infected26.3   NHLBI   R01            Host specific responses GUIDO
                                              7R01HL075766-05      SILVESTRI, in SIV-induced hematosuppressio
HIV   [t220]-hiv-infected26.2   NINDS   R01            Macrophages, Neuronal K+ Channels and HIV-1 Dementi
                                              5R01NS041862-06      XIONG, HUANGUI
HIV   [t220]-hiv-infected26.2   NIMH    R01            Microglia GREENE, WARNER C.
                                              5R01MH064396-05 and the Neuropathogenesis of HIV Disease
HIV   [t220]-hiv-infected26.1   NIAID   U01            Multicenter MARGOLICK, JOSEPH B (Baltimore Site)
                                              5U01AI035042-14       Aids Cohort Study- Part B.
HIV   [t220]-hiv-infected26.1   NIMH    R21            HIV Mediated Dysfunction of Neural
                                              5R21MH072534-02 HAUGHEY, NORMAN J. Progenitor Cells
HIV   [t220]-hiv-infected 26    NIAID   R21            AIDS Diarrhea and Antiretroviral Drug Absorption
                                              5R21AI064021-02      FITZGERALD, DANIEL W.
HIV   [t220]-hiv-infected 26    NIAID   R13            HIV Pathogenesis
                                              1R13AI068352-01      PARSLOW, TRISTRAM G.
HIV   [t220]-hiv-infected 26    NIAID   R01            HIV Compartmentalization in Women:Virus & CTL Respon
                                              5R01AI052015-05      WEISER, BARBARA
HIV   [t220]-hiv-infected 26    NHLBI   R01            Pathogenesis of HIV-Related Emphysema: T Cells, smok
                                              5R01HL083482-02      BECK, JAMES M.
HIV   [t220]-hiv-infected 26    NIAID   K23            Clinical    SPACEK, LISA A.
                                              5K23AI060384-03 Algorithms to Monitor HIV Treatment in Uganda
HIV   [t220]-hiv-infected 26    NIDA    R01            HIV Disease, Drug MARIANNA K.
                                              5R01DA016551-04      BAUM, Abuse, & Nutrient Therapy in Botswan
HIV   [t220]-hiv-infected25.8   NHLBI   R01            Mechanisms of Atherosclerosis C. CVD in HIV+ Women
                                              1R01HL083760-01      KAPLAN, ROBERT and
HIV   [t220]-hiv-infected25.8   NIAID   R01            HIV Protease Inhibitors and Hepatic Lipid Dysregulation
                                              5R01AI057189-03      HYLEMON, PHILLIP B.
HIV   [t220]-hiv-infected25.7   NIAID   U01            ADULT AIDS CLINICAL TRIAL AUSTIN.
                                              3U01AI032782-13S2 O'BRIEN, WILLIAM UNIT
HIV   [t220]-hiv-infected25.5   NIAID   R01            Pathogenesis of Neonatal SIV Infection
                                              5R01AI062410-03      VEAZEY, RONALD S.
HIV   [t220]-hiv-infected25.5   NINDS   R01            Molecular GENDELMAN, HOWARD E.
                                              5R01NS034239-12 Mechanisms of HIV Neuropathogenesis
HIV   [t220]-hiv-infected25.4   NIMH    R01            SIV, IDO, and the Host Response in neuroAIDS
                                              1R01MH072477-01A2 FOX, HOWARD S.
HIV   [t220]-hiv-infected25.3   NINDS   R01            HIV-1 C Clade Progression and NeuroAIDS
                                              1R01NS055653-01A1 KUMAR, MAHENDRA
HIV   [t220]-hiv-infected25.3   NIAID   R21            Regulation GARCIA-MARTINEZ, J. VICTOR.
                                              1R21AI068589-01A1 of Nef Activities by Phosphorylation
HIV   [t220]-hiv-infected25.2   NIAID   R01            Hiv Immune Reactivity 'in Vivo'A. 'In Vitro'
                                              5R01AI051181-05      SMITH, KENDALL and
HIV   [t220]-hiv-infected25.2   NIAID   R01            HIV Resistance and Treatment Strategies
                                              5R01AI029193-16      D'AQUILA, RICHARD T.
HIV   [t220]-hiv-infected25.1   NIAID   R01            Adjuvanted MURPHEY-CORB, MICHAEL A.
                                              5R01AI058801-03       Epitope Vaccine to Target HIV Reservoirs
HIV   [t220]-hiv-infected25.1   NIAID   R21            Mitochondria And Metabolic Complications Of HIV
                                              5R21AI063995-02      TEBAS, PABLO
HIV   [t220]-hiv-infected 25    NHLBI   R01            Matrix remodeling in the lung during HIV infection
                                              5R01HL083481-02      SCHNAPP, LYNN M.
HIV   [t220]-hiv-infected 25    NICHD   R01            Health of LOCKMAN, SHAHIN
                                              5R01HD044391-04 HIV-Infected Mothers after pMTCT, Botswana
HIV   [t220]-hiv-infected24.9   NIAID   R01            Whole       BARRATT-BOYES, Using Dendritic Cells
                                              5R01AI052052-05 Autologous SIV Vaccine SIMON M.
HIV   [t220]-hiv-infected24.8   NIAID   R44            HIV-1       HUMEAU, gene therapy
                                              5R44AI051908-04vector mediatedLAURENT M. for HIV-1 infection
HIV   [t220]-hiv-infected24.7   NIAID   U01            COLORADO ADULT AIDS CLINICAL
                                              3U01AI032770-13S2 CAMPBELL, THOMAS B. TRIALS UNIT
HIV   [t220]-hiv-infected24.6   NIMH    R21            Monocyte ESSER, URSULA
                                              5R21MH074383-02 Brain Infiltration in Acute SIV Infection
HIV   [t220]-hiv-infected24.6   NIMH    R01            HIV-1 Infection Increases Brain
                                              5R01MH068213-04 PULLIAM, D LYNN. Amyloid Beta
HIV   [t220]-hiv-infected24.5   NIAID   R01            Molecular Mechanisms of HIV's Immune Evasion
                                              5R01AI046998-07      COLLINS, KATHLEEN L.
HIV   [t220]-hiv-infected24.5   NIMH    R01            Molecular FOX, HOWARD S.
                                              5R01MH073490-02 Aspects of CNS Dysfunction Due to SIV/HIV
HIV   [t220]-hiv-infected24.4   NIAID   R01            Impact of SLEASMAN, JOHN W.
                                              2R01AI047723-04A1 HIV-1 Genotype on Therapy Response in Childr
HIV   [t220]-hiv-infected24.4   NIAID   R01            An in vitro Model for HIV Latency in Primary Cells
                                              1R01AI070010-01      ZACK, JEROME A.
HIV   [t220]-hiv-infected24.4   NHLBI   R01            Host specific responses in SIV-induced hematosuppressio
                                              5R01HL075766-04      STAPRANS, SILVIJA I.
HIV   [t220]-hiv-infected24.4   NIAID   K01            Variation Immune Activation D.
                                              5K01AI066917-02 in BARBOUR, JASONin HIV-1 Infected Persons
HIV   [t220]-hiv-infected24.3   NIAID   U01            PEDIATRIC AIDS CLINICAL TRIAL UNIT
                                              5U01AI032907-14      LUZURIAGA, KATHERINE F.
HIV   [t220]-hiv-infected24.2   NIAID   R01            Induction Apoptosis by HIV-1
                                              5R01AI045343-06 ofMAYER, LLOYD F. Infected Monocytic Cells
HIV   [t220]-hiv-infected24.2   NICHD   R01            HIV-1 Variants within PBMC Subpopulations in Infants
                                              5R01HD032259-12      GOODENOW, MAUREEN M.
HIV   [t220]-hiv-infected24.2   NIAID   K23            The Impact SAITOH, AKIHIKO Receiving HAART
                                              5K23AI056931-03       of HLA in Children
HIV   [t220]-hiv-infected24.2   NHLBI   R01            Modeling MITTLER, JOHN E.
                                              5R01HL072631-05 Pulmonary HIV-Cytokine Interactions
HIV   [t220]-hiv-infected24.2   NIMH    R21            Transmigration of HIV-1-infected cells
                                              5R21MH070279-02 WILLIAMS, KEVIN JON. in NeuroAIDS
HIV   [t220]-hiv-infected24.1   NIAAA   R01            The Effect VEAZEY, SIV Pathogenesis
                                              5R01AA013563-05 Alcohol onRONALD S.
HIV   [t220]-hiv-infected24.1   NIAID   R21            Do antibodies to HIV-Tat regulate redox status in HIV?
                                              1R21AI064104-01A2 HERZENBERG, LEONORE A.
HIV   [t220]-hiv-infected24.1   NIDA    R01            Opioids & MCCANCE-KATZ, ELINORE F.
                                              3R01DA013004-09S1HIV Medications: Interactions in Drug Abusers
HIV   [t220]-hiv-infected 24    NIAID   R01            Murine      LITTMAN, DAN R.
                                              5R01AI033856-14 Model System for HIV Pathogenesis
HIV   [t220]-hiv-infected23.9   NIAID   U01            VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
                                              3U01AI046339-05S2 HAAS, DAVID W.
HIV   [t220]-hiv-infected23.8   NIAID   U01            SAN DIEGO AIDS CLINICAL TRIAL A.
                                              3U01AI027670-18S2 BENSON, CONSTANCE UNIT
HIV   [t220]-hiv-infected23.8   NIAID   R01            GBV-C       STAPLETON, JACK T.
                                              5R01AI058740-03 Natural History, Epidemiology, HIV Interaction
HIV   [t220]-hiv-infected23.8   NHLBI   R01            HAART       LIPSHULTZ, STEVEN EDWARD.
                                              5R01HL078522-03 Associated Cardiotoxicity in HIV-Infected Children
HIV   [t220]-hiv-infected23.8   NIGMS   S06            Functional Map
                                                                   NOEL, RICHARD J.
                                              5S06GM008239-210011 -- HIV Tat Second Exon in Cytokine Regu
HIV   [t220]-hiv-infected23.7   NIAID   R01            Induction HIV-specific Immune
                                              1R01AI066992-01A1 ofGANDHI, RAJESH T. Responses
HIV   [t220]-hiv-infected23.7   NIDA    R01            Cannabinoid effects PATRICIA E.
                                              1R01DA020419-01A1 MOLINA,on HIV/AIDS
HIV   [t220]-hiv-infected23.6   NIAID   R01            Role of      THOMAS, GARY
                                              5R01AI049793-06 PACS-1 in HIV-1 Immunoevasion
HIV   [t220]-hiv-infected23.6   NIAID   U01            ADULT AIDS CLINICAL TRIALS UNIT
                                              3U01AI027661-19S3 BALFOUR, HENRY H.
HIV   [t220]-hiv-infected23.6   NIMH    R01            Neuroprotective Effects of Minocycline in Lentiviral Inf
                                              5R01MH069116-03 ZINK, M CHRISTINE.
HIV   [t220]-hiv-infected23.6   NIAID   R01            Killer Cells & Viral Load inKATHERINE Infection
                                              5R01AI032391-14       LUZURIAGA, Vertical HIV F.
HIV   [t220]-hiv-infected23.4   NIAID   K23            Immune FEENEY, MARGARET
                                              5K23AI052078-05 Control of HIV in Children E.
HIV   [t220]-hiv-infected23.4   NICHD   R01            Maternal MACTUTUS, CHARLES F.
                                              5R01HD043680-04 HIV: Developmental Neurotoxicity
HIV   [t220]-hiv-infected23.4   NIMH    K23            Cognitive TATE, DAVID F.
                                              5K23MH073416-02 Performance and Diffusivity in HIV Patients
HIV   [t220]-hiv-infected23.3   NIMH    R01            HIV Neurocognitive Disorders:
                                              2R01MH058076-09A2 ELLIS, RONALD J. A Randomized Clinical Tria
HIV   [t220]-hiv-infected23.3   NIDA    R01            Opioids      MCCANCE-KATZ, ELINORE F.
                                              5R01DA013004-09 & HIV Medications: Interactions in Drug Abusers
HIV   [t220]-hiv-infected23.3   NCI     R01            Src Family SMITHGALL, THOMAS E.
                                              2R01CA081398-06A2 Kinases as Molecular Targets for HIV/Nef
HIV   [t220]-hiv-infected23.3   NIAID   K24            Antiviral    CU-UVIN, SUSAN
                                              5K24AI066884-02 Therapy and HIV in the Genital Tract of Women
HIV   [t220]-hiv-infected23.2   NIMH    R01            Viral/Cell GARTNER, SUZANNE
                                              5R01MH067831-04 Determinants of HIV Drug Resistance in CNS
HIV   [t220]-hiv-infected23.2   NIAID   R01            A Novel, WATKINS, DAVID I.
                                              5R01AI049120-06 Logical Approach to HIV Vaccine Development
HIV   [t220]-hiv-infected23.1   NIAID   K23            ANTIRETROVIRAL PHARMACOLOGY IN THE GENITAL
                                              5K23AI054980-04       KASHUBA, ANGELA D.
HIV   [t220]-hiv-infected23.1   NICHD   K23            Response WESTER, CAROLYN
                                              5K23HD049292-02 of Genital Tract HIV-1 to HAART:Role of HSV-
HIV   [t220]-hiv-infected23.1   NIGMS   S06            Role of Nef BOND, VINCENT
                                                                    in
                                              2S06GM008248-200060 T-cell DepletionC.
HIV   [t220]-hiv-infected 23    NIAID   R01            Mechanisms Underlying Dendritic Cell-mediated HIV Tran
                                              1R01AI068493-01       WU, LI
HIV   [t220]-hiv-infected22.9   NIMH    R21            Macrophages, HAART, and HIV G.
                                              5R21MH072388-02 VALCOUR, VICTOR dementia in Thailand
HIV   [t220]-hiv-infected22.9   NINDS   R01            Tat, NADPH oxidase, and HIV-dementia J
                                              5R01NS046267-03       BRUCE-KELLER, ANNADORA
HIV   [t220]-hiv-infected22.9   NINDS   R01            HIV-1 in POTASH, MARY JANE
                                              5R01NS043110-05 macrophages: Role in AID's Dementia
HIV   [t220]-hiv-infected22.8   NCI     K07            Treatment DIAMOND, CATHERINE A.
                                              5K07CA096480-05 and Outcome of AIDS-related Lymphoma
HIV   [t220]-hiv-infected22.8   NIDA    R01            Modulation PETERSON, PHILLIP K. Function by Opiates
                                              5R01DA004381-21       of Cell-Mediated Immune
HIV   [t220]-hiv-infected22.8   NIAID   R01            Combinatorial use of anti-HIV RNA-based therapeutics
                                              5R01AI042552-09       ROSSI, JOHN J.
HIV   [t220]-hiv-infected22.8   NIAID   R01            HIV-related blood dendritic cell
                                              1R01AI065275-01A2 WILSON, CARA C. dysfunction
HIV   [t220]-hiv-infected22.7   NICHD   R01            Clinical     KUHN, of Transient Nevirapine Resistance
                                              5R01HD047177-03Relevance LOUISE
HIV   [t220]-hiv-infected22.7   NIAID   R01            A randomized trial of HAART in acute/early HIV Infection
                                              5R01AI056990-03       MARGOLICK, JOSEPH B.
HIV   [t220]-hiv-infected22.6   NIAID   R21            Structural GARCIA-MARTINEZ, J. VICTOR
                                              1R21AI068527-01A2 Plasticity of an HIV-1 Nef/Pak-2 Activity Surface
HIV   [t220]-hiv-infected22.6   NIGMS   R01            HIV 1 transcription: Tat/novel cofactors/Mechanisms
                                              5R01GM067538-02 PARADA, CAMILO A.
HIV   [t220]-hiv-infected22.5   NIAID   U01            Haitian Program for Research and
                                              3U01AI058257-03S1 PAPE, JEAN WILLIAM.Training in HIV/AIDS
HIV   [t220]-hiv-infected22.5   NIAID   R01            Statistical Methods in HIV Vaccine Efficacy Trials
                                              2R01AI054165-04       GILBERT, PETER B.
HIV   [t220]-hiv-infected22.4   NHLBI   R01            Pneumocystis in PathogenesisM. HIV-associated Emphys
                                              7R01HL083461-03       MORRIS, ALISON of
HIV   [t220]-hiv-infected22.4   NIAID   R01            MechanismPETERLIN, BORIS MATIJA.
                                              5R01AI051165-05        of HIV 1 Nef Action
HIV   [t220]-hiv-infected22.4   NCI     R01            HPV & cervix neoplasia in a large, long-term HIV+ cohort
                                              5R01CA085178-07       STRICKLER, HOWARD D.
HIV   [t220]-hiv-infected22.3   NIDA    R01            Drug Abuse, Substance P
                                              3R01DA012815-07S1 HO, WENZHE and HIV
HIV   [t220]-hiv-infected22.2   NIAID   R01            Effect       CULLEN, on retroviruses and retrotransposon
                                              5R01AI065301-02of APOBEC3G BRYAN R.
HIV   [t220]-hiv-infected22.2   NIAID   U01            U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS
                                              3U01AI046376-05S2 JAIN, MAMTA K.
HIV   [t220]-hiv-infected22.2   NINDS   R01            Monocyte WILLIAMS, KENNETH C
                                              2R01NS040237-06 Traffic and Neuropathogenesis of AIDS
HIV   [t220]-hiv-infected22.2   NIAID   R01            Clinical Significance of LISA M.
                                              1R01AI065217-01A1 DEMETER,HIV Replication Fitness
HIV   [t220]-hiv-infected22.2   NIAID   U19            (CHAVI) HAYNES, BARTON F.
                                              5U19AI067854-02 Center for HIV/AIDS Vaccine Immunology
HIV   [t220]-hiv-infected22.1   NHLBI   R01            STUDIES JOLICOEUR, PAUL
                                              5R01HL083470-02 OF LUNG DISEASES OF HIV TRANSGENIC M
HIV   [t220]-hiv-infected22.1   NICHD   R21            Sex Differences in Plasma HIV-1 RNA Concentrations
                                              1R21HD051450-01A2 CONNICK, ELIZABETH
HIV   [t220]-hiv-infected 22    NIAID   R21            HIV and the Mucosal KAROL
                                              3R21AI054146-02S1 SESTAK, Immune System:New Vaccine Strate
HIV   [t220]-hiv-infected 22    NIGMS   S06            Protein Profiling
                                                                    MELENDEZ-GUERRERO, LOYDA M.
                                              5S06GM008224-220042 of Putative Anti-retroviral Factors in Place
HIV   [t220]-hiv-infected21.9   NHLBI   R21            Iron as      KALLIANPUR, Toxic R.
                                              1R21HL087726-01Nutritional Modifier ASHA Neuropathy HIV/AIDS
HIV   [t220]-hiv-infected21.8   NIMH    R01            Suppression HIV-1 in CNS by
                                              1R01MH074392-01A2 AMINI, SHOHREHnovel protein-ST John's Wo
HIV   [t220]-hiv-infected21.8   NIMH    R01            Mechanisms of HAD: JOAN CCL2, BBB and HIV infectio
                                              1R01MH075679-01A1 BERMAN, Role ofW.
HIV   [t220]-hiv-infected21.7   NIAID   U01            NORTHWESTERN ADULT AIDS
                                              3U01AI025915-18S2 MURPHY, ROBERT L.CLINICAL TRIALS UNI
HIV   [t220]-hiv-infected21.7   NIDDK   R21            HIV-1 Tat GARRY, ROBERT F.
                                              5R21DK070551-02 modulation of HCV replication and pathogenesi
HIV   [t220]-hiv-infected21.7   NIMH    R21            Delineating Viral Determinants of R.
                                              5R21MH075636-02 PRASAD, VINAYAKA HAD using SCID Mice
HIV   [t220]-hiv-infected21.6   NIAID   R01            Methods DEGRUTTOLA, VICTOR HIV-Infected Patient
                                              5R01AI051164-05 for Long-Term Follow-Up of G.
HIV   [t220]-hiv-infected21.6   NIAID   R01            Mechanism/predictors LISA M.
                                              1R01AI071212-01A2 FRENKEL, of genital/rectal HIV shedding durin
HIV   [t220]-hiv-infected21.6   NIMH    R01            CSF & Lymphocyte Dynamics W.
                                              2R01MH062701-06A1 PRICE, RICHARD in HIV Infection
HIV   [t220]-hiv-infected21.6   NIAID   U19            Viral and Host Determinants of F.
                                              5U19AI067854-020001HAYNES, BARTONHIV-1 Transmission
HIV   [t220]-hiv-infected21.5   NHLBI   R01            Macaque CHEN, ZHENG W.
                                              5R01HL064560-09 Models of AIDS-Related Tuberculosis and T Ce
HIV   [t220]-hiv-infected21.5   NIAID   K08            A longitudinal study of HIV-1 infection in Uganda
                                              5K08AI052791-05      CURLIN, MARCEL E.
HIV   [t220]-hiv-infected21.5   NIMH    K23            Cognitive TATE, DAVID F.
                                              7K23MH073416-03 Performance and Diffusivity in HIV Patients
HIV   [t220]-hiv-infected21.5   NIAID   R01            Role of     ANSARI, AFTAB A.
                                              5R01AI027057-17 T Cell Immunity in Primate AIDS
HIV   [t220]-hiv-infected21.5   NIMH    R01            Choroid     MEEKER, RICK B.
                                              2R01MH063646-05 plexus macrophages in FIV neuropathogenesis
HIV   [t220]-hiv-infected21.4   NIAID   U01            ADULT AIDS CLINICAL TRIALS
                                              3U01AI027663-18S2 HAVLIR, DIANE V. UNIT
HIV   [t220]-hiv-infected21.4   NIDA    R01            Natural     COTTON, DEBORAH J.
                                              5R01DA019841-07History of Hepatitis C Infection in HIV Disease
HIV   [t220]-hiv-infected21.4   NIAID   U01            A Cambodian Clinical Research Network for HIV & TB
                                              5U01AI061736-03      THIM, SOK
HIV   [t220]-hiv-infected21.3   NIAID   U19            The effect of ART on LINDA-GAIL
                                              5U19AI053217-050003BEKKER, rates and transmission of TB
HIV   [t220]-hiv-infected21.3   NIAID   K23            Immune EMU, BRINDA
                                              5K23AI062279-03 Correlates of Protection in Drug-Resistant HIV
HIV   [t220]-hiv-infected21.3   NIAID   K24            MIDCAREER INVESTIGATOR AWARD IN PATIENT OR
                                              5K24AI055293-04      WANKE, CHRISTINE A.
HIV   [t220]-hiv-infected21.2   NIMH    R01            Astrocytes SCHNELL, MATTHIAS JOHANNES.
                                              5R01MH074375-02 and Restricted HIV-1 Replication
HIV   [t220]-hiv-infected21.2   NIAID   K23            DOT-HARRT for HIV-Infected South African Adults
                                              1K23AI068582-01      NACHEGA, JEAN
HIV   [t220]-hiv-infected21.2   NIAID   R01            Working Models of HIV Persistence & Evolution
                                              1R01AI063926-01A2 ROUZINE, IGOR M.
HIV   [t220]-hiv-infected21.2   NIAID   U19            Dendritic RINALDO, CHARLES R.
                                              5U19AI055794-04 Cell-Based Immunotherapy for HIV Infection
HIV   [t220]-hiv-infected21.2   NIAID   R01            Innovative methods for measuring antiretroviral exposure
                                              5R01AI065233-02      GREENBLATT, RUTH M.
HIV   [t220]-hiv-infected21.1   NIMH    K01            Effects of LANGFORD, TERESA DIANNE.
                                              5K01MH071206-03 HIV PIs on CNS endothelial cells in NeuroAIDS
HIV   [t220]-hiv-infected21.1   NIAID   K23            Compartmentalization of HIV within the genital tract
                                              5K23AI055276-04      SMITH, DAVID M.
HIV   [t220]-hiv-infected21.1   NIAID   U01            Pediatric YOGEV, RAM
                                              5U01AI027559-18 AIDS Clinical Trials Unit
HIV   [t220]-hiv-infected 21    NHLBI   R01            Effects     SMITH, PHILIP Sleep & Daytime Function
                                              5R01HL079554-03of HIV & HAART on L.
HIV   [t220]-hiv-infected 21    NHLBI   R01            Cardiovascular Status of STEVEN EDWARD.
                                              5R01HL072705-06      LIPSHULTZ, HAART-Exposed Infants/Childre
HIV   [t220]-hiv-infected 21    NIAID   U19            COLLABORATIVE AIDS PROGRAMME
                                              3U19AI051794-05S1 ABDOOL KARIM, SALIM S. OF RESEARCH
HIV   [t220]-hiv-infected 21    NIAID   R01            High Throughput Screening to Identify
                                              1R01AI070039-01A1 DOUGHERTY, JOSEPH P.Antagonists of HIV-
HIV   [t220]-hiv-infected 21    NICHD   K24            Pediatric JOHN-STEWART, GRACE C.
                                              1K24HD054314-01 HIV-1 in Africa: Pathogenesis and Management
HIV   [t220]-hiv-infected20.9   NIDA    R01            Mouse       VOLSKY, DAVID J.
                                              5R01DA017618-03Model of HIV-1 Infection and Drug Addiction
HIV   [t220]-hiv-infected20.9   NIMH    R21            Hepatitis Virus Brain Infection
                                              5R21MH073422-02 C LASKUS, TOMASZ in HCV/HIV Coinfection
HIV   [t220]-hiv-infected20.9   NIDA    R01            Natural History of Hepatitis ROBERT.
                                              3R01DA019841-07S1 HORSBURGH, C Infection in HIV Disease
HIV   [t220]-hiv-infected20.9   NIAID   R13            Case CFAR Meeting: HIV Pathogenesis
                                              1R13AI071692-01      LEDERMAN, MICHAEL M.
HIV   [t220]-hiv-infected20.9   NIAID   R21            Etiology    FRENKEL, LISA M.
                                              5R21AI065288-02 of mastitis in HIV-1 infected women
HIV   [t220]-hiv-infected20.9   NIAID   R21            SIV-Specific CD8+ T-Cell Immunity
                                              1R21AI068488-01A2 O'CONNOR, DAVID H. in Mauritian Cynos
HIV   [t220]-hiv-infected20.9   NIMH    R21            PET Imaging of Amyloid in the L.
                                              5R21MH072529-02 ACHIM, CRISTIAN HIV Brain
HIV   [t220]-hiv-infected20.9   NIAID   R01            HIV-1       KASHANCHI, Peptide
                                              5R01AI043894-08Inhibition using Tat FATAH Derivatives
HIV   [t220]-hiv-infected20.8   NIAAA   R01            Alcohol       AIDS: Pathogenesis and Immunity in Macaqu
                                              5R01AA015045-03 andKUMAR, ANIL
HIV   [t220]-hiv-infected20.8   NIAID   U19            Virology & Immunology
                                              5U19AI051915-050003SHAO, YIMING
HIV   [t220]-hiv-infected20.8   NIAID   R01            Passive-Active Immunization Strategies Against Pediatric
                                              1R01AI062518-01A2 MARTHAS, MARTA L.
HIV   [t220]-hiv-infected20.7   NICHD   R21            Antiretroviral Pharmacology/Lactating Mother/Infants
                                              5R21HD051470-02      MIROCHNICK, MARK H.
HIV   [t220]-hiv-infected20.6   NIAID   R21            The Role CD4 on Natural Killer Cells
                                              5R21AI058786-02 ofBERNSTEIN, HELENE B.
HIV   [t220]-hiv-infected20.6   NIAID   R01            Molecular Interactions of NefJACEK
                                              5R01AI042561-09      SKOWRONSKI, and AIDS Pathogenesis
HIV   [t220]-hiv-infected20.6   NIAID   U19            Early antiretroviral treatment
                                              5U19AI053217-050002VIOLARI, AVYE in children
HIV   [t220]-hiv-infected20.6   NIA     R01            HIV Associated CNS Dysfunction with Aging
                                              5R01AG023471-04      HAUGHEY, NORMAN J.
HIV   [t220]-hiv-infected20.5   NIAID   R01            Effects     LORI, FRANCO
                                              5R01AI056982-04 of Adjuvants on Therapeutic DNA Vaccination
HIV   [t220]-hiv-infected20.5   NHLBI   R01            CD4 Immune Reconstitution in SIV Infection
                                              5R01HL075833-04      VILLINGER, FRANCOIS J.
HIV   [t220]-hiv-infected20.5   NIAID   R01            HIV/AIDS Intravirion HUI
                                              5R01AI052732-03      ZHANG, Reverse Transcription and Virucides
HIV   [t220]-hiv-infected20.5   NIDA    R21            RNA editing and its inhibition of HIV-1 replication in human
                                              1R21DA022162-01      HOSHINO, YOSHIHIKO
HIV   [t220]-hiv-infected20.4   NIAID   R01            Generalized Varying-Coefficient Partially Linear Models
                                              5R01AI059773-02      LIANG, HUA
HIV   [t220]-hiv-infected20.4   NIDA    R01            Drug Abuse, Substance P and HIV
                                              5R01DA012815-07      HO, WENZHE
HIV   [t220]-hiv-infected20.4   NINDS   R21            Mode of virus transmission into the
                                              1R21NS054573-01A2 POTASH, MARY JANE brain in a mouse mod
HIV   [t220]-hiv-infected20.3   NIAID   R01            Cell-mediated immune responses to HIV-1 in GALT
                                              5R01AI057020-04      SHACKLETT, BARBARA L.
HIV   [t220]-hiv-infected20.3   NHLBI   R01            Immune NORRIS, KAREN A.
                                              5R01HL077095-02 response to Pneumocystis in simian model of AID
HIV   [t220]-hiv-infected20.3   NIAID   U19            Bacterial conjugate SHABIR
                                              5U19AI053217-050004MADHI, vaccines AHMED.
HIV   [t220]-hiv-infected20.3   NIMH    R01            Tat, amyloid beta and brain endothelial barrier function
                                              5R01MH072567-02 TOBOREK, MICHAL J.
HIV   [t220]-hiv-infected20.3   NIAID   R37            Analytic    ROBINS, JAMES M.
                                              5R37AI032475-15 Methods for HIV Treatment and Co-Factor Effect
HIV   [t220]-hiv-infected20.2   NIAID   R01            HIV-1       MULLINS, JAMES I.
                                              5R01AI058894-03and Host Cell Changes in Disease Progression
HIV   [t220]-hiv-infected20.2   NIAID   R21            Neisseria CHEN, TIE
                                              5R21AI062269-03 gonorrhoeae enhances HIV - 1 infection
HIV   [t220]-hiv-infected20.2   NICHD   R01            Elucidating TEMOSHOK, LYDIA
                                              5R01HD048154-03       Biopsychosocial Mediators of HIV Progression
HIV   [t220]-hiv-infected20.2   NIAID   R01            Biochemical Mechanism of HIV N. Integration
                                              5R01AI039394-11      ENGELMAN, ALAN DNA
HIV   [t220]-hiv-infected20.1   NIAID   R01            Immunogenetic /Immunoregulatory Basis for HIV-1 Respo
                                              5R01AI056980-03      PLUMMER, FRANCIS A.
HIV   [t220]-hiv-infected20.1   NIAID   K08            Mapping PLENGE, ROBERT M.
                                              5K08AI055314-03 HIV/AIDS genes with haplotype-based strategies
HIV   [t220]-hiv-infected20.1   NIAID   R21            Toward      FARZAN, MICHAEL R.
                                              1R21AI070070-01 a new world monkey model of HIV-1 infection
HIV   [t220]-hiv-infected 20    NIDA    R01            Cocaine/Immuno and Neuropathogenesis of HIV-1 Infecti
                                              5R01DA012366-08      NAIR, MADHAVAN P.
HIV   [t220]-hiv-infected19.9   NIAID   K08            Factors/HIV-1 Nef's MARTHADirect Immune Evasion
                                              1K08AI068449-01      LEWIS, Ability to J.
HIV   [t220]-hiv-infected19.8   NIAID   R37            OccurrenceMULLINS, JAMES I. HIV-1 Infection
                                              5R37AI047734-07       and Outcome of Dual
HIV   [t220]-hiv-infected19.8   NIAID   R01            Immune ROSE, JOHN K.
                                              5R01AI045510-08 Responses to VSV/HIV/SIV Hybrids in Macaques
HIV   [t220]-hiv-infected19.8   NIAID   R21            Topical     HAASE, ASHLEY T.
                                              1R21AI071976-01 Microbicide Against SIV and Chlamydia
HIV   [t220]-hiv-infected19.8   NIAID   R01            The Role Natural Killer T Cells
                                              7R01AI054206-04 ofUNUTMAZ, DERYA in HIV Infection
HIV   [t220]-hiv-infected19.8   NIAID   K08            Impact      KOVAL, CHRISTINE E.
                                              5K08AI051154-05 of efavirenz resistance mutations on HIV-1
HIV   [t220]-hiv-infected19.8   NHLBI   K23            HIV-Related Proteinuria and K.
                                              5K23HL073682-04      GUPTA, SAMIR Endothelial Dysfunction
HIV   [t220]-hiv-infected19.8   NIAID   R01            Osteoporosis in HIV-infected Postmenopausal Women
                                              5R01AI065200-02      SHANE, ELIZABETH J.
HIV   [t220]-hiv-infected19.7   NIAID   K08            Defining BLISH, CATHERINE A.
                                              1K08AI068424-01 Immune Deficits in HIV-1 Infected Women
HIV   [t220]-hiv-infected19.7   NIAID   U19            COLLABORATIVE AIDS PROGRAMME
                                              3U19AI051794-04S3 ABDOOL KARIM, SALIM S. OF RESEARCH
HIV   [t220]-hiv-infected19.7   NIAID   U01            ADULT AIDS CLINICAL TRIALS
                                              3U01AI025903-18S2 CLIFFORD, DAVID B.UNIT
HIV   [t220]-hiv-infected19.7   NHLBI   R01            Sleep Studies in HIV+ Older Children/Adolescents
                                              5R01HL079533-03      SHEARER, WILLIAM THOMAS.
HIV   [t220]-hiv-infected19.6   NHLBI   R01            Sleep Studies in HIV+ WILLIAM THOMAS.
                                              3R01HL079533-03S1 SHEARER,Older Children/Adolescents
HIV   [t220]-hiv-infected19.6   NIMH    R21            Development of Neuronal gene
                                              7R21MH072355-02 BUCH, SHILPA J. therapy for HIV-dementia
HIV   [t220]-hiv-infected19.5   NIMH    R01            HIV in Women: Depression and
                                              5R01MH067501-04 EVANS, DWIGHT L. Immunity
HIV   [t220]-hiv-infected19.5   NIAID   U01            MIAMI ADULT AIDS CLINICAL TRIALS GROUP, AACTG
                                              3U01AI027675-18S2 FISCHL, MARGARET A.
HIV   [t220]-hiv-infected19.5   NIAID   R21            Recruitment and activation of RSK2 by HIV Tat
                                              5R21AI065248-02      OTT, MELANIE
HIV   [t220]-hiv-infected19.5   NIAID   R01            Compounds That Inhibit HIV M.
                                              1R01AI068501-01A1 REKOSH, DAVIDRev Function
HIV   [t220]-hiv-infected19.5   NIMH    R03            T cell loss SCOFIELD, VIRGINIA
                                              5R03MH077470-02 in a murine model for AIDS
HIV   [t220]-hiv-infected19.4   NIAID   R01            Role of HLA-G on HIV Evasion of
                                              1R01AI065361-01A2 BARKER, EDWARD NK Cells
HIV   [t220]-hiv-infected19.4   NIAID   R21            Antigen     CANADAY, DAVID
                                              5R21AI062368-02 Processing in HIV-infected Individuals
HIV   [t220]-hiv-infected19.4   NIAID   R01            Transmission & PathogenesisCECILIA R5 SHIVs
                                              5R01AI046980-07      CHENG-MAYER, of X4 & C.
HIV   [t220]-hiv-infected19.4   NICHD   R01            Standard zidovudine plus MARC J.
                                              1R01HD052461-01A2 LALLEMANT, infant nevirapine to prevent peri
HIV   [t220]-hiv-infected19.3   NIAID   K08            Viral Constraints on SIV Escape from Cytotoxic T Lympho
                                              1K08AI069995-01      YEH, WENDY
HIV   [t220]-hiv-infected19.3   NIAID   R01            CD40        CHOUGNET, CLAIRE A.
                                              5R01AI056927-02Ligand Dysregulation and HIV Pathogenesis
HIV   [t220]-hiv-infected19.3   NHLBI   R01            HIV/TB      WEIDEN, MICHAEL
                                              5R01HL057879-08 Interaction in the Lung D.
HIV   [t220]-hiv-infected19.3   NIAID   K23            Genital     GRAHAM, SUSAN Women
                                              1K23AI069990-01 HIV-1 Shedding amongMARIE. Starting Second-L
HIV   [t220]-hiv-infected19.3   NIAID   U01            Southern RICHMAN, DOUGLAS D.
                                              5U01AI043638-09 California Primary Infection Program
HIV   [t220]-hiv-infected19.2   NIMH    R01            Study of GIULIAN, DANA
                                              5R01MH073476-02 Novel Brain Toxin Associated With HIV Dementia
HIV   [t220]-hiv-infected19.2   NIAID   U19            Family treatment
                                              5U19AI053217-050001WOOD, ROBIN
HIV   [t220]-hiv-infected19.2   NIMH    K08            Interaction RUMBAUGH, MMP in Neuropathogenesis
                                              5K08MH072389-03 of HIV Tat and JEFFREY A.
HIV   [t220]-hiv-infected19.2   NIDA    R01            Cocaine/Immuno and Neuropathogenesis of HIV-1 Infecti
                                              7R01DA012366-09      NAIR, MADHAVAN P.
HIV   [t220]-hiv-infected19.2   NIAID   R01            Procaspase 8 Activation by HIV Protease
                                              5R01AI062261-03      BADLEY, ANDREW D.
HIV   [t220]-hiv-infected19.1   NIAID   U01            AIDS CLINICAL TRIALS GROUP -
                                              3U01AI025897-17S2 FEINBERG, JUDITH E. ACTU
HIV   [t220]-hiv-infected 19    NIAID   R01            IL-15 treatment od SIV-infectedD.
                                              5R01AI062437-02      KATSIKIS, PETER non-human primates
HIV   [t220]-hiv-infected 19    NIAID   K23            Immunity Early Syphillis: Pathway to HIV Coinfection
                                              5K23AI062439-02 inSALAZAR, JUAN C.
HIV   [t220]-hiv-infected 19    NIAID   R44            A Novel     BRUE, VESTA
                                              5R44AI052634-04 Technology to Improve HIV Medication Complian
HIV   [t220]-hiv-infected18.9   NIAID   R21            Nucleoside BUOLAMWINI, JOHN K.Mitochondrial Toxicity
                                              5R21AI065372-02       Transporters In HAART
HIV   [t220]-hiv-infected18.9   NICHD   R01            Immunization by HIV exposure during chemoprophylaxis
                                              5R01HD040102-02      FRENKEL, LISA M.
HIV   [t220]-hiv-infected18.9   NHLBI   R01            Viral Protein Mediators of HIV-Related Pulmonary Hypert*
                                              5R01HL083480-02      LASKY, JOSEPH A.
HIV   [t220]-hiv-infected18.8   NCI     R01            Stem Cell JOHNSON, R. PAUL.
                                              5R01CA073473-09 Gene Therapy for AIDS
HIV   [t220]-hiv-infected18.8   NIAID   R01            Mechanisms of CD4 RONALD S.
                                              3R01AI049080-05S1 VEAZEY, Depletion and Proliferation in SIV
HIV   [t220]-hiv-infected18.8   NIAID   U19            COLLABORATIVE AIDS PROGRAMME OF RESEARCH
                                              5U19AI051794-05      ABDOOL KARIM, SALIM S.
HIV   [t220]-hiv-infected18.8   NHLBI   R01            ChemokineKIRSCHNER,the HIV-1/SIV Infected Lung
                                              5R01HL072682-05       Dynamics in DENISE E.
HIV   [t220]-hiv-infected18.7   NIAID   K08            The role SAGAR, MANISH
                                              5K08AI052759-05 of viral diversity in HIV-1 drug resistance
HIV   [t220]-hiv-infected18.7   NIMH    K24            Mentoring KAPLAN, ANDREW H.
                                              5K24MH071191-03 Junior Faculty: Access to HIV Care
HIV   [t220]-hiv-infected18.7   NIAID   U01            ADULT AIDS CLINICAL TRIALS
                                              3U01AI046383-05S2 MELLORS, JOHN W. UNIT
HIV   [t220]-hiv-infected18.7   NIMH    R01            Promoting GOLIN, CAROL E.
                                              5R01MH069989-02 Safer Behavior Among Viremic HIV+Patients
HIV   [t220]-hiv-infected18.7   NHLBI   R01            Viral Protein Mediators of HIV-Related Pulmonary Hypert*
                                              3R01HL083480-02S1 LASKY, JOSEPH A.
HIV   [t220]-hiv-infected18.7   NIAID   K08            Latent       and HIV-1 specific N.
                                              5K08AI051191-05 virusBLANKSON, JOEL immunity in LTNPs
HIV   [t220]-hiv-infected18.6   NIMH    K23            HIV,Race GIORDANO, the Highly Active Therapy Era
                                              5K23MH067505-04 and Survival inTHOMAS P.
HIV   [t220]-hiv-infected18.6   NIAID   U01            ADULT AIDS CLINICAL RICHARD C.
                                              3U01AI027658-18S2 REICHMAN, TRIALS UNIT (AACTU)
HIV   [t220]-hiv-infected18.6   NHLBI   R01            Alveolar DIAZ, PHILIP T.
                                              5R01HL083478-02 macrophage proteomics in HIV-induced emphyse
HIV   [t220]-hiv-infected18.5   NICHD   R01            HIV Protective Immunity and Perinatal Exposure
                                              5R01HD042402-05      KUHN, LOUISE
HIV   [t220]-hiv-infected18.5   NINDS   R01            Monocyte/macrophage activities and trafficking in HIVE
                                              5R01NS047031-03      RAPPAPORT, JAY
HIV   [t220]-hiv-infected18.4   NIDA    R21            A Healthy COPENHAVER, MICHAEL
                                              1R21DA021093-01A1Transition for Newly Released HIV-Infected Pris
HIV   [t220]-hiv-infected18.4   NIAID   R01            The Role Vpr in HIV-1 MICHAEL I.
                                              5R01AI033776-13 ofBUKRINSKY, Nuclear Translocation
HIV   [t220]-hiv-infected18.4   NIAID   R01            HIV-1       MALLAL, SIMON ALEXANDER.
                                              5R01AI060460-03adaptation to HLA-restricted immune responses
HIV   [t220]-hiv-infected18.4   NIDA    R03            Functional PAUL, ROBERT H.
                                              1R03DA022137-01 Neuroimaging of Cognitive Dysfunction in HIV-
HIV   [t220]-hiv-infected18.3   NIAID   R01            Phenotypes of HIV-1 Integrases
                                              1R01AI063973-01A2 ROBINSON, WILLIAM E.
HIV   [t220]-hiv-infected18.3   NIAID   U01            Antiviral   MONTANER, LUIS J.
                                              5U01AI065279-02 activity of Peg-IFN alpha in chronic HIV-1
HIV   [t220]-hiv-infected18.3   NINDS   R01            MR Spectroscopy of SIV RAMON GILBERTO
                                              5R01NS050041-02      GONZALEZ, Brain Injury
HIV   [t220]-hiv-infected18.3   NIDDK   R01            BFGF Low RAY, PATRICIO and
                                              2R01DK049419-09A2 Affinity ReceptorsE. HIVAN
HIV   [t220]-hiv-infected18.3   NIAID   K24            Improving HAUBRICH, RICHARD H.
                                              1K24AI064086-01A1 Antiretroviral Management for HIV
HIV   [t220]-hiv-infected18.2   NIDDK   R21            HIV ImpairsBUKRINSKY, MICHAEL I.
                                              5R21DK072926-02       Reverse Cholesterol Transport
HIV   [t220]-hiv-infected18.1   NIAID   R03            Highthroughput Assay for Inhibitors of HIV PR Activation
                                              5R03AI067022-02      KAPLAN, ANDREW H.
HIV   [t220]-hiv-infected18.1   NIMH    R01            Microglia, Cytokines and HIV
                                              3R01MH055477-10S1 LEE, SUNHEE C.
HIV   [t220]-hiv-infected18.1   NHLBI   R01            Viral Host MANKOWSKI, JOSEPH L.
                                              5R01HL078479-03 Interactions in SIV Cardiac Dysfunction
HIV   [t220]-hiv-infected18.1   NIDA    R01            Efficacy    ARNSTEN, JULIA H.
                                              5R01DA015302-04 and cost of HAART DOT in methadone clinics
HIV   [t220]-hiv-infected18.1   NIAID   R37            Cost-effectiveness of preventing HIV ALAN.
                                              2R37AI042006-10A1 FREEDBERG, KENNETHcomplications
HIV   [t220]-hiv-infected18.1   NHLBI   R01            Alveolar Macrophage Innate
                                              2R01HL063655-06A2 KOZIEL, HENRY Immune Function in HIV
HIV   [t220]-hiv-infected18.1   NIDDK   R01            HIV Antiretroviral Drugs and Glucose Metabolism
                                              5R01DK066999-03      GRUNFELD, CARL
HIV   [t220]-hiv-infected 18    NHLBI   R01            Endothelial GOLDMAN, Due to HIV-1 Protease Inhibitors
                                              5R01HL072711-05       Dysfunction MITCHELL
HIV   [t220]-hiv-infected 18    NIAID   R01            Novel Biological Activities of Anti-Viral
                                              3R01AI052039-04S1 FORTHAL, DONALD N. Antibody
HIV   [t220]-hiv-infected 18    NIAID   R21            Pseudovirions of HIV to target viral accessory proteins
                                              5R21AI057092-02      CIMARELLI, ANDREA
HIV   [t220]-hiv-infected17.9   NIDA    R01            HIV+ Drug WALDROP-VALVERDE, DRENNA G.
                                              5R01DA018066-02 Users: Neurocognitive Aspects of ARV Adhere
HIV   [t220]-hiv-infected17.9   NHLBI   R01            SIV Cardiomyopathy: Pathogenesis and Prevention
                                              5R01HL075836-04      SHANNON, RICHARD P.
HIV   [t220]-hiv-infected17.8   NHLBI   K08            Redox       IEONG, MICHAEL H.
                                              5K08HL073671-04Regulated HIV Expression in Alveolar Macrophage
B, GEOFFREY S.
DANIEL SETH.


D, DEBORAH



O, ROBERT F.
 NATHANIEL R.



EZ-SCARANO, FRANCISCO A.


UR, JUSTIN C
IS, DAVID M.




, CHRISTOPHER C.
Y, VLADIMIR A.



R, ELLEN ELIZABETH.


ON, DOLORES MURL.
TS, JANICE E.


ZU, BRUCE T.
ON, DOLORES MURL.

MARTINEZ, J. VICTOR.
MARTINEZ, J. VICTOR.




RE, FRANCIS J.
NS, EDWARD BRICE.
N, NANCY S.



RADFORD A
KE, TERRENCE F.

 JEFFREY N.

 LNIK, ROBERT J.




 S, STEVEN D.
WITZ, MARTIN H.
A, CECILIA M.
 EWART, GRACE C.

LAND, RAYMOND SCOTT.

 S, KENNETH C
R, ROBERT P.




TS, JANICE E

WSKI, JOSEPH L




, WARNER C.




ANNOU, THEODORA

STEIN, DAVID A.
 GREGORY P.
SOULEYMANE
LD, ANNE E.



ERG, ERIC S.

 RICHARD D.


O, ROBERT F.




AD, PAUL A.


CE, JEFFREY C.



SON, MARIO
WSKI, PAWEL S.
ANT, MARC J.



CHRISTOPHER H.

CHRISTINA M



EZ-SCARANO, FRANCISCO A

 IS, DAVID M.
 ES, VICENTE




N, KENNETH E.
ET, CLAIRE A.

ST, WILLIAM F
 ERG, PHILIP D.
H, SERENA S.
N, OPENDRA
 MARY JANE


, WARNER C.
ICK, JOSEPH B.
Y, NORMAN J.
ALD, DANIEL W.
W, TRISTRAM G.



ARIANNA K.
ROBERT C.
N, PHILLIP B.
 WILLIAM AUSTIN.

MAN, HOWARD E.


MARTINEZ, J. VICTOR.

A, RICHARD T.
 Y-CORB, MICHAEL A.



T-BOYES, SIMON M.
, LAURENT M.
LL, THOMAS B.


, KATHLEEN L.

AN, JOHN W.

NS, SILVIJA I.
R, JASON D.
GA, KATHERINE F.

OW, MAUREEN M.


S, KEVIN JON.

BERG, LEONORE A.
E-KATZ, ELINORE F.


, CONSTANCE A.
 ON, JACK T.
TZ, STEVEN EDWARD.
PATRICIA E.

R, HENRY H.

GA, KATHERINE F.
MARGARET E.
US, CHARLES F.


 E-KATZ, ELINORE F.
ALL, THOMAS E.

R, SUZANNE

A, ANGELA D.



R, VICTOR G.
KELLER, ANNADORA J
 MARY JANE
D, CATHERINE A.
ON, PHILLIP K.



ICK, JOSEPH B.
MARTINEZ, J. VICTOR

AN WILLIAM.


N, BORIS MATIJA.
ER, HOWARD D.



S, KENNETH C

 BARTON F.

K, ELIZABETH

EZ-GUERRERO, LOYDA M.
PUR, ASHA R.


, ROBERT L.

 VINAYAKA R.
TOLA, VICTOR G.
 BARTON F.




, DEBORAH J.

 LINDA-GAIL

CHRISTINE A.
L, MATTHIAS JOHANNES.


, CHARLES R.
LATT, RUTH M.
RD, TERESA DIANNE.



TZ, STEVEN EDWARD.
KARIM, SALIM S.
RTY, JOSEPH P.
EWART, GRACE C.


RGH, C ROBERT.
AN, MICHAEL M.

OR, DAVID H.




 S, MARTA L.
NICK, MARK H.
EIN, HELENE B.
ONSKI, JACEK

Y, NORMAN J.

ER, FRANCOIS J.

O, YOSHIHIKO


 MARY JANE
ETT, BARBARA L.
HABIR AHMED.
K, MICHAL J.




AN, ALAN N.
R, FRANCIS A.
 ROBERT M.
 MICHAEL R.




CHRISTINE E.

ELIZABETH J.
ATHERINE A.
 KARIM, SALIM S.

R, WILLIAM THOMAS.
R, WILLIAM THOMAS.


MARGARET A.


D, VIRGINIA


MAYER, CECILIA C.
ANT, MARC J.

 ET, CLAIRE A.
  MICHAEL D.
 , SUSAN MARIE.
N, DOUGLAS D.


GH, JEFFREY A.

ANDREW D.
G, JUDITH E.



WINI, JOHN K.
 KARIM, SALIM S.
NER, DENISE E.

 ANDREW H.




NO, THOMAS P.
AN, RICHARD C.



 AVER, MICHAEL
 KY, MICHAEL I.
 SIMON ALEXANDER.

ON, WILLIAM E.

EZ, RAMON GILBERTO

CH, RICHARD H.
 KY, MICHAEL I.
 ANDREW H.

WSKI, JOSEPH L.

ERG, KENNETH ALAN.


N, MITCHELL
L, DONALD N.
 LI, ANDREA
 P-VALVERDE, DRENNA G.
N, RICHARD P.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:4
posted:3/1/2012
language:English
pages:16